Cargando…
Development of a 2′,4′-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo
Recent advances in RNA interference (RNAi)-based drug development have partially allowed systemic administration of these agents in vivo with promising therapeutic effects. However, before chemically modified small-interfering RNAs (siRNAs) can be applied clinically, their in vivo effects should be...
Autores principales: | Wada, Shunsuke, Obika, Satoshi, Shibata, Masa-Aki, Yamamoto, Tsuyoshi, Nakatani, Moeka, Yamaoka, Tetsuji, Torigoe, Hidetaka, Harada-Shiba, Mariko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464879/ https://www.ncbi.nlm.nih.gov/pubmed/23344237 http://dx.doi.org/10.1038/mtna.2012.32 |
Ejemplares similares
-
Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in
Atherogenic Diet-induced Hypercholesterolemic Mice
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2012) -
Superior Silencing by 2′,4′-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2′,4′-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2012) -
Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2021) -
Development of Antisense Drugs for Dyslipidemia
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2016) -
2′,4′‐BNA/LNA with 9‐(2‐Aminoethoxy)‐1,3‐diaza‐2‐oxophenoxazine Efficiently Forms Duplexes and Has Enhanced Enzymatic Resistance
por: Kishimoto, Yuki, et al.
Publicado: (2020)